Literature DB >> 7694531

Inactivation of leukotriene C4 in the airways and subsequent urinary leukotriene E4 excretion in normal and asthmatic subjects.

J Y Westcott1, N F Voelkel, K Jones, S E Wenzel.   

Abstract

Leukotrienes (LT) are synthesized in the lung during asthmatic reactions and mediate certain inflammatory symptoms. Pulmonary metabolism and clearance of exogenously added peptidoleukotrienes were studied in nonasthmatics, asthmatics, and asthmatics challenged with allergen. [3H]LTC4 and [14C]dextran were instilled into the airways, and bronchoalveolar lavage fluid (BALF) was obtained 15 min later. After comparing the [3H]/[14C] ratio of the instilled solution with that in BALF, 77% of LT were found to have been removed from the airways of nonasthmatics, and 72% of unchallenged asthmatics. Allergen administration to asthmatics 1 min before LT instillation inhibited LT transfer out of the airways by 26%, compared with asthmatics not challenged with allergen. This decrease in the removal of LT from the airways during allergic reactions could potentiate the physiologic effects of LT produced in the airways. The predominant LT in BALF was LTE4, constituting 56% of the LT in asthmatics and 61% in nonasthmatics. The percentage of LTE4 in BALF increased to 87% in allergen-stimulated asthmatics (p < 0.05 compared with the two other groups), this again reflecting decreased transfer of LT out of the lung rather than an increase in metabolism. Urinary excretion of LT metabolites occurred rapidly, the majority being excreted excreted within 6 h after instillation. LTE4, the major urinary LT metabolite identified by high-performance liquid chromatography, was a similar percentage concentration in the three groups and, thus, can be accurately used as an index of LT synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694531     DOI: 10.1164/ajrccm/148.5.1244

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.

Authors:  T C O'Shaughnessy; P Georgiou; K Howland; M Dennis; C H Compton; N C Barnes
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

3.  Peptidoleukotriene (PLT) release and absorption from the airways of the isolated perfused guinea pig lung following chemical and antigenic challenge.

Authors:  R A Kovelesky; P R Byron; J Venitz
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

4.  Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.

Authors:  Arash Mohebati; Ginger L Milne; Xi Kathy Zhou; Anna J Duffield-Lillico; Jay O Boyle; Allison Knutson; Brian P Bosworth; Philip J Kingsley; Lawrence J Marnett; Powel H Brown; Esther G Akpa; Eva Szabo; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

5.  Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.

Authors:  P Tagari; C Brideau; C Chan; R Frenette; C Black; A Ford-Hutchinson
Journal:  Agents Actions       Date:  1993-09

6.  Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.

Authors:  Anna J Duffield-Lillico; Jay O Boyle; Xi Kathy Zhou; Aradhana Ghosh; Geera S Butala; Kotha Subbaramaiah; Robert A Newman; Jason D Morrow; Ginger L Milne; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

7.  Effects of fluticasone propionate on arachidonic acid metabolites in BAL-fluid and methacholine dose-response curves in non-smoking atopic asthmatics.

Authors:  S E Overbeek; J M Bogaard; I M Garrelds; F J Zijlstra; P G Mulder; H C Hoogsteden
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.